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Abstract (MAX 255 words) 
 
Research question: 
An important discussion point prior to chemotherapy is ovarian toxicity, a side effect 
that profoundly affects young women with cancer. Their quality of life after 
successful treatment, including the ability to conceive, is a major concern. We 
asked whether serum Anti-Müllerian hormone (AMH) measurements before 
chemotherapy for two most common malignancies are predictive of long-term 
changes in ovarian reserve? 
Design 
A prospective cohort study measured serum AMH in 66 young, female, lymphoma 
and breast cancer patients, before and at 1 year and 5 years after chemotherapy, 
compared with 124 healthy volunteers of the same age range (18-43). 
Contemporaneously, patients reported their menses and live births during 5-year 
follow-up. 
Results  
After adjustment for age, serum AMH was 1.4 times higher (95% CI, 1.1-1.9, 
p<0.02) in healthy volunteers than in cancer patients even before chemotherapy. 
There was a strong correlation between baseline and 5-year AMH in the breast 
cancer group (p<0.001, regression coefficient = 0.58, 95% CI, 0.29-0.89). There 
was no significant association between presence of menses at 5 years and serum 
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AMH at baseline (likelihood ratio test (LRT) from logistics regression analysis; 
p=0.37).  
Conclusions  
Reproductive age women with malignancy have lower serum AMH than healthy 
controls even before starting chemotherapy. Pre-chemotherapy AMH was 
significantly associated with long term ovarian function in women with breast 
cancer. AMH measurements at key time points could be utilised as a reproductive 
health advisory tool for young women with cancer. Our results highlight the 
unsuitability of return of menstruation as a clinical indicator of ovarian reserve post-
chemotherapy.  
Key words (6): 
AMH, ovarian toxicity, ovarian reserve, oncofertility 
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Key message (50 words) 
Reproductive age women with malignancy have lower serum AMH than healthy 
controls before starting chemotherapy. Pre-chemotherapy AMH relates to long term 
ovarian function in women with breast cancer. Return of menstruation is unsuitable 
as a clinical indicator of ovarian reserve post-chemotherapy.  
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INTRODUCTION  
 
Early detection of cancer and improving survival rates have resulted in young 
women diagnosed with cancer having increased life expectancy (Quaresma et al., 
2015). Their quality of life after successful treatment, including the ability to 
conceive, is a major concern (Howard-Anderson et al., 2012). Unfortunately, long-
term effects of chemotherapy upon ovarian function in women of reproductive age 
are difficult to quantify (Dunlop e Anderson, 2015). Young women who regain 
menses may yet have undergone premature depletion of ovarian follicles and have 
less time in which to become pregnant due to early menopause (Bath et al., 2003; 
Larsen et al., 2003; Reh et al., 2008).  
Measuring ovarian reserve before and after cancer treatment could inform patients 
regarding their individual risk of future subfertility and premature menopause 
(Barnabei et al., 2015). At present, serum Anti-Müllerian hormone (AMH) is the 
most accurate biological marker of ovarian reserve (Broekmans et al., 2006; 
Fleming et al., 2015; Iliodromiti et al., 2015). There is growing evidence for its use 
in women undergoing chemotherapy (Anderson et al., 2013; Dillon et al., 2013; 
Henry et al., 2014; Freour et al., 2017), however long-term studies with repeated 
AMH measurements are still missing due to the challenges of extended follow-up 
in this population.  Most of the longitudinal studies published so far have studied 
into different time frames for AMH measurements, older age groups (particularly 
breast cancer), and used previous suboptimal assays of AMH.  Most of the studies 
have 2- year follow-ups (Anders et al., 2008; Decanter et al., 2010; Hamy et al., 
2014; Freour et al., 2017; Decanter et al., 2018).  
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 Our study assesses whether serum AMH, as a marker of ovarian function, may 
facilitate reproductive counselling in women treated with chemotherapy. 
Therefore, we assessed the correlation between serum AMH at baseline and 1 and 
5 years after starting chemotherapy. Additionally, pre-chemotherapy serum AMH 
was compared between healthy volunteers and cancer patients. Furthermore, we 
investigated the association between pre-chemotherapy AMH and the presence of 
menses at 5-year follow-up. 
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MATERIAL AND METHODS 
Ethics approval 
Approval was gained from Coventry and Warwickshire Research Ethics Committee 
and each clinical site. The trial was included in the UK Clinical Research Network 
(UKCRN: 8445) Portfolio. Trial registration number: ISRCTN28988709. 
Study design 
A prospective cohort study measured the effect of chemotherapy on ovarian 
function, assessed by serum AMH during 5 years. Patients aged 18-43 years with 
newly diagnosed breast cancer or lymphoma were recruited across multiple 
oncology clinics in the UK and followed up for 5 years.  Female patients meeting 
the criteria were identified through the direct healthcare team and recruited 
consecutively where possible. Women with advanced breast cancer (stage IV), 
previous chemotherapy/radiotherapy, or oophorectomy were excluded.  
The control group comprised healthy volunteer women of the same age range, 
without prior exposure to chemotherapy, radiotherapy or oophorectomy.  All 
participants had serum AMH measured at recruitment (before chemotherapy in 
cancer patients) and at scheduled follow-up intervals of 1 and 5 years where 
possible. A detailed medical questionnaire was completed at each blood test.  
Information concerning the type and stage of cancer, dose, duration and number of 
courses of chemotherapy was provided from the medical records by oncology 
teams using a proforma. 
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Study procedures 
Participants’ whole blood samples were collected locally in serum tubes that were 
sent immediately by first class post, to arrive at the laboratory within 24 hours. 
Cancer patients had their initial samples obtained before the first dose of 
chemotherapy.  
Upon arrival at the central laboratory, samples were processed on day of receipt 
according to assay manufacturer’s instructions, rendered acellular by centrifugation 
and prepared serum was stored in aliquots at -20°C.   
Samples were initially analysed for AMH using modified gen II protocol (using 
buffer) and then verified using the new automated Access assay, Beckman Coulter 
Diagnostics (detection limit 0.14 pmol/L, mean inter- and intra-assay coefficients of 
variation 2.8 % and 1.7% respectively). Researchers and laboratory personnel were 
blinded to either patient clinical progress or AMH concentration. The results were 
not used to manage cancer patients.  
 
 
Statistical analysis 
Baseline characteristics of study participants were summarized by means and 
standard deviations (SDs) for continuous outcome variables and counts and 
percentages for categorical variables. Analysis of variance (ANOVA) and 
independent samples t-tests and Tukey’s honest significance (HSD) test were used 
to assess differences in mean responses between cancer groups for continuous 
outcomes, based on assumed approximate normality, and Fisher’s exact test was 
used for comparing categorical variables between groups.  
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AMH data were log-transformed prior to analysis. Differences in AMH between 
cancer groups (breast, lymphoma and control) were visualized using box-plots. 
Linear regression analysis was used to model the relationship between serum AMH 
concentration, cancer group and age at baseline, and to model 5-year and 1-year 
AMH adjusting for age group (<37 years and 37+ years), baseline (pre-
chemotherapy) AMH and cancer group (control, breast or lymphoma) as 
explanatory variables. Logistics regression was used in an analogous manner to 
model binary out variables. All tests were considered to provide evidence of a 
statistically significant difference if p<0.05. All analysis was undertaken in R 
(Version 3.2.2). 
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RESULTS  
Baseline characteristics 
In total, 190 women completed the first medical questionnaire, comprising 54 breast 
cancer patients, 12 lymphoma patients and 124 healthy volunteers. Their baseline 
demographical and clinical characteristics are presented in Table 1.  The sample 
size comprised all those consented in oncology units over a two-year period.  
Chemotherapy protocols are described in Table 2. These were administered 
according to local protocols by the local care team.  Within the 5-year period, in the 
cancer group 13/66 (19.6%) patients died and 10/66 (15.1%) declined final follow-
up or were lost to follow-up. 
Baseline results 
Prior to chemotherapy, there was a significant difference in serum AMH between 
cancer patients and healthy controls (z-test; p=0.02) Figure 1. Regression analysis 
of log-transformed (base 10) AMH, after adjusting for age and other confounding 
factors (smoking, use of COCP), showed that serum AMH was 1.4 (95% CI; 1.1 to 
1.9) times higher in the control group than in the cancer group (breast and 
lymphoma combined).  
Longitudinal results 
Overall, 49/54 (90.7%) of breast cancer patients had detectable AMH at 1-year 
follow-up and 35/41 (85.3%) at 5-years. While serum AMH at 1-year was low in this 
group, it remained similar between 1-year and 5-year follow-ups, which is 
interesting because some further decline might have been expected over this time 
period as observed in the volunteer group (Figure 2). All women with breast cancer 
aged ≤37 at diagnosis with pre-chemotherapy AMH >11 pmol/ had detectable 
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AMH>2 pmol/L at 5-year follow-up. In contrast to the breast cancer group, in the 
lymphoma group, all patients had detectable AMH at 1-year and 5-year follow-ups. 
The recovery of ovarian function was more noticeable in young patients with 
Hodgkin lymphoma who received ABVD regimen. Figure 3 shows summary plots 
of regression for AMH at 5-year follow-up in relation to chemotherapy regimen.  
 
 
Is pre-chemotherapy AMH predictive of post-chemotherapy AMH at 1 and 5 
years? 
1-year  
As shown in Figure 3, there was a significant association between baseline and 1-
year AMH for breast cancer (p<0.001; regression coefficient = 0.56, 95%CI 0.3 to 
0.7), and lymphoma patients (p<0.001; regression coefficient = 1.6, 95% CI 1.1 to 
2.2). The overall percentage of variance explained by the model was 90.2%. 
5-year 
Figure 4 presents regression models for 5-year data showing significant 
associations between baseline AMH and 5-year AMH for the breast cancer 
(p<0.001; regression coefficient = 0.58, 95%CI 0.29 to 0.89), but not the lymphoma 
group (p=0.343). The overall percentage of variance explained by the model was 
81.3%. 
Prevalence of chemotherapy-related amenorrhea and reported live births. 
There was no significant association between menses at 5 years and serum AMH 
measurements before chemotherapy (likelihood ratio test (LRT) from logistics 
regression analysis; p=0.37).  
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At 5-year follow-up, serum AMH was significantly lower in women who reported 
amenorrhea over last 12 months in comparison to women who still reported 
presence of menstrual cycles either regular or irregular (p=0.003). 
However, amongst women who reported presence of menses at 5-year follow-up 
(regular or irregular), 7/17 (40%) had AMH less than 1. 
Amongst the 41 cancer patients who completed 5-year follow-up, 3 have reported 
life births, all of whom were patients with Hodgkin lymphoma aged ≤31 at diagnosis 
treated with ABVD.  
None of the breast cancer patients had had a live birth. Although many women with 
breast cancer would have been advised against pregnancy while they were taking 
hormone therapy, the decision would be multifactorial.  We therefore do not know 
how many breast cancer patients actively tried to become pregnant during the study 
period. 
There were no important adverse events or unintended effects in this study.   
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DISCUSSION 
First, our study confirmed that in young women with cancer, serum AMH is already 
significantly lower before chemotherapy than in healthy volunteers. In the breast 
cancer group at diagnosis, we found significantly lower serum AMH compared to 
healthy volunteers, adjusting for age, parity, smoking, use of contraceptive pill and 
BMI. This differs from some previous reports (Lutchman Singh et al., 2007; Yu et 
al., 2010; Su et al., 2013), but agrees with others (Bala et al., 2016). For example, 
Su et al, in 2013, found that 108 patients with breast cancer had similar serum AMH 
to healthy controls (Su et al., 2013), however, a more recent study found 
significantly reduced AMH compared to healthy volunteers (Bala et al., 2016). This 
is a particularly important finding for women considering fertility preservation before 
chemotherapy. Importantly, our results’ prediction model estimates a 6 year 
difference in ‘fertility age’ between healthy volunteers and women newly diagnosed 
with cancer, which may be useful in clinical practice while advising patients about 
fertility preservation. Interestingly this difference was stable across the whole age 
span. 
The biological explanation of diminished ovarian reserve in cancer sufferers, even 
before gonadotoxic therapy, is currently unclear. At present, it is uncertain whether 
there is a cause and effect relationship: does the lower ovarian reserve in some 
way predispose to breast cancer initiation, or does it arise in response to the 
malignant disease or depend upon its stage?  Titus et al., reported that women with 
BRCA1 mutation may have lower levels of serum AMH as a result of impaired DNA 
repair mechanisms in oocytes. Expression of BRCA1 gene in oocytes was found to 
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be important in the process of ovarian aging related to DNA double–strand break 
repair (Titus et al., 2013). Others have reported that BRCA mutation may be 
associated with a lower age at natural menopause that would support the finding of 
reduced ovarian reserve in this group (Finch et al., 2013; Lin et al., 2013). In 
contrast, others have recently found similar serum AMH concentrations in healthy 
BRCA1/2 mutation carriers age 26-40, compared with the general population 
(Michaelson-Cohen et al., 2014; Gunnala et al., 2019).  
Apart from widespread metastatic disease, the mechanisms potentially responsible 
for decreased fertility potential in women with other malignancies are uncertain. The 
consumptive character of systemic illness, increased catabolism, and elevated 
stress hormones cause an increase in prolactin, which may impact on ovulation, 
have all been proposed as possible pathways affecting ovarian reserve (Agarwal e 
Said, 2004). Additionally, poor health at the time of cancer diagnosis measured 
using serum markers e.g. increased C Reactive Protein (CRP), high body 
temperature and low haemoglobin have been shown to correlate with low serum 
AMH concentrations in girls aged 0-18 years, newly diagnosed with cancer (Van 
Dorp et al., 2014). The nature of this relationship is unclear, but the authors 
hypothesised that factors other than the size of the pool of follicles in the ovary 
might be contributing to low serum AMH in cancer patients.  
At a cellular level, AMH is one of the mediators of growth regulatory signals in breast 
tissue (Hoshiya et al., 2003). Exposure of breast cancer cells to AMH was found to 
inhibit growth and induce apoptosis. These authors suggested that lowered 
circulating AMH concentrations may be one of the predisposing factors for 
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developing breast cancer (Hoshiya et al., 2003). Similarly, Gupta et al (2005) 
suggested that AMH can suppress the growth of mammary tumours in vivo.  
This is the first study to report the use of AMH in a cancer population prospectively 
over 5 years using the most recent AMH assay with improved reliability. Importantly, 
in the breast cancer group, we found a strong association between AMH at 
baseline, at one year and at five years. While serum AMH post-chemotherapy was 
significantly reduced, there was no difference between 1-year and 5-year follow-
ups, which is interesting because decline might have been expected over this 
period due to time passed, however, this may perhaps be balanced by some 
ongoing recovery of follicular function in the ovary between 1 and 5 years post-
chemotherapy. Dynamics of folliculogenesis and steroidogenesis disrupted by 
chemotherapy might take significant amount of time to be restored to its normal 
function. Chemotherapy leads to loss of growing follicles in human ovaries (Meirow 
et al., 2010). In order to reliably measure remained ovarian reserve post-
chemotherapy using AMH, the test may need to be undertaken more than a year 
from chemotherapy. As AMH can be detected most strongly in growing pre-antral 
and small antral follicles, some weak signals have been observed in primary follicles 
but none in primordial follicles (Weenen et al., 2004). Depending on surviving pool 
of primordial follicles, if folliculogenesis is restored, on average it take >300 days 
for primordial follicle to reach preantral stage. 
 
This point requires confirmation by other studies but may offer reassurance to 
women with breast cancer who have been advised to delay pregnancy by 
oncologists. Patients may worry that delay may reduce their chances of pregnancy. 
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However, in our 5 year study, no further significant decline in ovarian reserve was 
observed beyond 1 year, despite the expected age-related decline . 
We conclude that AMH measurements at key time points could be utilised as a 
reproductive health advisory tool for young women with cancer, supporting our 
initial idea. Routine AMH measurements before chemotherapy may detect already 
diminished ovarian reserve and help women to make informed decisions about 
fertility preservation. Our study results highlight that all women with breast cancer 
had profoundly lowered ovarian reserve in comparison to volunteers at 5-year 
follow-up, regardless of chemotherapy protocol used. In that context, counselling 
for future fertility planning, however challenging at the time of cancer diagnosis, 
should be an integrated part of clinical care. Serial serum AMH can help to make it 
more individualised. 
Although, at 5-year follow-up, AMH was significantly lower in the non-menstruating 
group, some women still reported presence of menses despite very low AMH. 
Additionally, there was no association between pre-chemotherapy AMH and 
presence of menses at 5-year follow-up, which highlights the unsuitability of return 
of menstruation as a clinical indicator of changes in the ovarian reserve in such 
patients.  Return of menses post-chemotherapy does not reflect the degree of 
damage done to the ovaries and may be falsely reassuring. 
Importantly, our samples were analysed using recent automated assays, with improved 
precision. Many previous studies used older AMH assays with poor reproducibility (Rustamov et 
al., 2012). The AMH assay has historically had a number of technical concerns. Lack of 
international standards for AMH, differences in sample handling, different antibodies used by kits 
and late discovery of complement interference in updated Gen II AMH assay all resulted in 
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inconsistent data being published on AMH. These problems questioned the validity of AMH 
assay and delayed its widespread use in clinical practice. However, the new automated assays 
seem to have finally overcome those issues offering better precision, lower limit of quantification 
and short test duration and better availability (Li et al., 2016; Pigny et al., 2016). 
Additionally, using recently developed ultrasensitive AMH assays allows the 
detection of extremely low serum concentrations which might offer an advantage in 
serial AMH measurements post-chemotherapy in order to improve understanding 
of dynamics of follicular recovery (Decanter et al., 2014).  
 
Our lymphoma group was not large enough to be suitable for subanalysis. 
Considering the paucity of long-term, prospective, longitudinal studies assessing 
changes in ovarian reserve in this group of patients, we present our descriptive 
findings, which remain valuable for clinicians and as a contribution to future meta-
analyses. Our findings are consistent with previous results on Hodgkin’s lymphoma 
survivors which concluded that women aged <32 years, treated with ABVD had a 
significantly reduced risk of premature ovarian failure in comparison to older 
population using different regimen (Van Der Kaaij et al., 2012).  
 
Considering 5-year follow-up of breast cancer patients, we found that baseline pre-
chemotherapy serum AMH was significantly associated with AMH after 1 and 5 
years.  Su et al. (2010) enrolled women ~2 years post-chemotherapy for breast 
cancer and found that patients had lower AMH than controls and that women 
menstruating following chemotherapy had higher AMH than those without menses 
(Su, 2010). Conversely, another study found that AMH and antral follicle count 
(AFC) were the most sensitive markers of reduced ovarian reserve in the cancer 
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population (Partridge et al., 2010). Anderson et al. recruited women with breast 
cancer (mean age 42.6) with two-year follow-up, showing that women with return 
of menses (n=9) had higher pre-chemotherapy AMH than amenorrhoeic women 
(n=30) (Anderson et al., 2013).  Similarly, Anderson and Cameron found that pre-
chemotherapy AMH was higher in menstruating women at 5-year follow-up. In 
contrast to our study, their multivariate logistic regression model found AMH to be 
a significant predictor for menses post-chemotherapy (Anderson e Cameron, 
2011b). Most previous studies evaluated AMH during 12-24 months follow-up, while 
our study assessed AMH prospectively over 5 years (Yu et al., 2010; Anderson e 
Cameron, 2011a; Decanter et al., 2018; Passildas et al., 2019). Additionally, some 
studies used previously stored blood samples obtained at different times 
postchemotherapy (Hamy et al., 2016). Issues surrounding the development of 
AMH assays highlighted sample instability as an important factor (Han et al., 2014). 
Other studies included patients who were older at the time of recruitment, including 
women up to age of 50, who would have had a reduced ovarian reserve already 
(Anderson et al., 2013; Henry et al., 2014).  Furthermore, heterogeneity of data 
(Rosendahl et al., 2010; Dillon et al., 2013), and combined use of ovarian 
suppression protocols (Kim et al., 2018) may have contributed to the suboptimal 
quality of evidence regarding the use of AMH in cancer populations.  Our study has 
overcome those issues providing prospective data collection in selected younger 
women, using the most reliable AMH assay. 
The recruitment of young women with breast cancer into fertility studies is limited 
by the condition’s relatively rare presentation and difficulties with recruitment, both 
of which add to heterogeneity of the cancer groups. Oncologists initially focus on 
cancer treatment and patient survival rather than the long-term consequences of 
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gonadotoxic chemotherapy upon quality of life.  The findings of our study regarding 
AMH in young breast cancer patients should therefore be evaluated in a large, 
internationally recruiting study with long term follow-up and using an automated 
AMH assay. 
 
Our study does have some limitations.  We aimed to recruit two age-matched 
controls per case, however, some cases did not have exact age-matched controls. 
Statistical analysis was therefore performed with adjustment for age imbalance 
between groups.  
In order to ensure similar cohorts in cancer and non-cancer groups, women who 
reported having PCOS and AMH more than 40 pmol/L were not included in the 
analysis. Women suffering from PCOS are known to have higher AMH than normo-
ovulatory women (Iliodromiti et al., 2013; Bozdag et al., 2016; Pigny et al., 2016). 
The pattern of changes in serum AMH or ovarian reserve following chemotherapy 
might be different in women suffering from this endocrinopathy.  
The dropout rate over the 5-year period was higher than anticipated. Our patient 
groups were recruited from a range of centres and had demographics within the 
expected ranges, given our study’s focus on reproductive age women. Those lost 
to follow-up were deceased, seriously ill or had moved away from the recruiting 
centre. Our volunteer group comprised female hospital workers and was self-
selected so may not be fully reflective of the general population but individuals were 
drawn from a wide range of backgrounds. 
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In summary, our 5-year prospective study results support the use of repeat serum 
AMH measurements, as an ovarian reserve marker in reproductive age women 
suffering breast cancer and lymphoma. 
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